Dr. Priscilla Hsue, MD
Claim this profileUCSF/Zuckerberg San Francisco General Hospital
Studies HIV Infection
Studies Human Immunodeficiency Virus Infection
5 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Priscilla Hsue, MD is currently running
PCSK9 Inhibition
for HIV-Related Cardiovascular Risk
Atherosclerosis in the setting of HIV infection is distinct and includes increased vascular inflammation, worsened endothelial function, and a predominance of non-calcified plaque. These outcomes can be assessed using specialized noninvasive imaging which strongly predict future CV events in the general population. PCSK9 has emerged as an important pharmacologic target for cholesterol lowering in the general population and recent studies among individuals without HIV have shown that PCSK9 inhibitor therapy is safely tolerated and significantly reduces major CV events in the general population. The investigators will perform a clinical trial of PCSK9 inhibition in the setting of HIV infection. This will be a randomized, placebo-controlled study to evaluate the effects of PCSK9 inhibition on vascular inflammation, endothelial function, and non-calcified plaque using a PCSK9 inhibitor called alirocumab. This study will recruit 140 treated individuals with HIV who are aged 40 and older, with known CVD or risk factors for CVD and who have evidence of vascular inflammation at baseline. The primary and secondary objective of this study is to determine whether PCSK9 inhibition can improve arterial inflammation as assessed by FDG-PET/CT and endothelial function as assessed by flow mediated vasodilation. The investigators will correlate changes in arterial inflammation and endothelial function with lipids and markers of inflammation and immune activation. The tertiary objective is to perform a pilot evaluation of the impact of PCSK9 inhibition on non-calcified plaque as measured by coronary CT angiography. Non-calcified plaque measurements will be correlated with changes in lipid parameters and markers of inflammation and immune activation.
Recruiting1 award Phase 310 criteria
Bempedoic Acid
for HIV-Related Cardiovascular Disease
This is a randomized placebo-controlled study in treated and suppressed HIV-infected individuals aged ≥40 years with either known CVD or 1 CVD risk factor to study the effect of Bempedoic acid (BA) on safety, arterial inflammation as assessed by FDG-PET/CT, lipids, inflammation, immune activation, cardiometabolic indices, and non-calcified plaque (NCP) in the coronary arteries (assessed by coronary CT angiography, CCTA). This trial will be enrolled at UCSF and UCLA. Collaborators at Massachusetts General Hospital (MGH) will serve as the core facility for imaging.
Recruiting0 awards Phase 29 criteria
More about Priscilla Hsue, MD
Clinical Trial Related7 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Priscilla Hsue, MD has experience with
- AER002
- Ensitrelvir
- Bempedoic Acid
- Placebo
- Heart Failure Polypill
- Alirocumab
Breakdown of trials Priscilla Hsue, MD has run
HIV Infection
Human Immunodeficiency Virus Infection
Post-COVID Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Priscilla Hsue, MD specialize in?
Priscilla Hsue, MD focuses on HIV Infection and Human Immunodeficiency Virus Infection. In particular, much of their work with HIV Infection has involved treating patients, or patients who are undergoing treatment.
Is Priscilla Hsue, MD currently recruiting for clinical trials?
Yes, Priscilla Hsue, MD is currently recruiting for 2 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that Priscilla Hsue, MD has studied deeply?
Yes, Priscilla Hsue, MD has studied treatments such as AER002, Ensitrelvir, Bempedoic acid.
What is the best way to schedule an appointment with Priscilla Hsue, MD?
Apply for one of the trials that Priscilla Hsue, MD is conducting.
What is the office address of Priscilla Hsue, MD?
The office of Priscilla Hsue, MD is located at: UCSF/Zuckerberg San Francisco General Hospital, San Francisco, California 94110 United States. This is the address for their practice at the UCSF/Zuckerberg San Francisco General Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.